Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB-102 in Adult Patients With Schizophrenia
NCT07369154Phase 3Recruiting
- Sponsor
- LB Pharmaceuticals
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- T-cell Engagers, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of LP-102 in schizophrenia, sponsored by LB Pharmaceuticals. Started Apr 2026; status: recruiting.
02
Drugs
LP-102
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07369154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07369154.